Feb. 13, 2023 – The Heart and Vascular Institute at UPMC in Central Pa. recently became the first in Pennsylvania to utilize the new Edwards PASCAL Precision transcatheter valve repair system, a U.S. Food and Drug Administration (FDA) approved treatment of mitral valve regurgitation or leaky heart valve.
The primary treatment for severe mitral valve regurgitation cases has been open-heart surgery to repair or replace the damaged valve. In recent years, as an alternative to surgery, doctors have turned to valve-repair devices that can be delivered less invasively, inserted by catheter through a vein in or near the groin. Until the FDA approved the Edwards PASCAL Precision system, there was only one device that had this capability in the U.S.
The Edwards PASCAL Precision system enables safe and effective treatment for patients with degenerative mitral valve disease. The system is designed for maneuverability and stability for precise navigation and implant delivery.